New treatment options for various cancer therapies appear to be extremely expensive and prices may increase further. The affordability and availability of life-saving medicines is therefore a key issue in the national health policies of all countries. International and European law grant several price-reducing options, including compulsory licensing. Still, countries are reluctant to apply for compulsory licensing and/or other regulatory options to curtail pharmaceutical prices. Why is that? Evaluating the options will support health policy decision-making on safeguarding access to affordable innovative medicines.

中文翻译：

---

打击过高的药品价格：评估选择

各种癌症疗法的新治疗方案似乎极其昂贵，而且价格可能会进一步上涨。因此，救生药物的可负担性和可用性是所有国家国家卫生政策中的一个关键问题。国际法和欧洲法律授予多种降价选择，包括强制许可。尽管如此，各国仍不愿申请强制许可和/或其他监管方案来降低药品价格。这是为什么？评估这些选项将支持有关保障获得负担得起的创新药物的卫生政策决策。